<DOC>
	<DOCNO>NCT00479934</DOCNO>
	<brief_summary>In vitro study show imatinib 1mM inhibits strongly growth cutaneous fibroblast . The hypothesis imatinib inhibits PDGFR know potential target molecule , recently also propose discovery autoantibodies activate PDGF receptor . Recent data indicate TGFb also potential target imatinib . Cutaneous scleroderma characterize progressive cutaneous fibrosis cause hyperactive dermal fibroblast . Since establish treatment skin sclerosis scleroderma currently available . This study test safety efficacy imatinib treatment patient scleroderma severe cutaneous involvement .</brief_summary>
	<brief_title>Efficacy Safety Imatinib Scleroderma</brief_title>
	<detailed_description>This study test efficacy tolerance patient high score induration ( modify Rodnan score &gt; 20/54 ) Comparison : 34 patient severe form cutaneous involvement evaluate double blind RCT compare imatinib 400mg/j placebo 6 month period . Efficacy assess use cutaneous induration scale skin biopsy , quality life questionnaire .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>More 18 year old Documented diagnostic scleroderma ( systemic cutaneous ) Severe cutaneous sclerodermia systemic sclerodermia mRodnan score &gt; 20/51 Ejection fraction 45 per cent cardiac ultrasound preinclusion study Woman efficient contraceptive method trail treatment 3 month end trial treatment All female patient reproductive potential must negative pregnancy test ( serum urine ) within 7 day prior enrolment Affiliated profit patient social security system Signed inform consent new systemic treatment , potentially interfere disease progression , begin 3 month prior start trial treatment Patient isolate cutaneous scleroderma treat drug potentially interfering course disease 4 week start trial ( Systemic corticosteroid , methotrexate , cyclophosphamide , bosentan ) Scleroderma `` en coup de sabre `` Severe organ failure anomaly blood chemistry/hematology ( bilirubin , SGOT , SGPT , creatinine &gt; 1,5 ´ upper normal limit , polymorphonuclear granulocyte less 1*10*9/l platelet less 50*10*9/l ) , Ongoing cancer Ejection fraction ≤ 45 per cent cardiac ultrasound pre inclusion study myocardial infarction le 6 mois pre inclusion visit Non control chronic illness ( diabetes , chronic kidney failure , chronic hepatitis , HIV infection ) , Major surgery less two week inclusion Pregnancy lactation Absence validate contraception childbearing woman . Contraindication imatinib mesylate treatment specify product specification Non observance anticipate absence inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>scleroderma</keyword>
	<keyword>imatinib</keyword>
	<keyword>PDGFR</keyword>
	<keyword>Rodnan</keyword>
</DOC>